Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1Amyloidosis 1

Interventions

Dexamethasone 64Cyclophosphamide 40Bortezomib 37Melphalan 24Lenalidomide 23Thalidomide 17pomalidomide 16fludarabine 12daratumumab 11carfilzomib 10Filgrastim 8Doxorubicin 8Busulfan 6Prednisone 5Peripheral Blood Stem Cell Transplantation 5Bendamustine Hydrochloride 5selinexor 4sargramostim 4isatuximab 4fludarabine phosphate 4Surveys and Questionnaires 4Etoposide 4Clarithromycin 4Calcium Dobesilate 4liposomal doxorubicin 3ixazomib 3Radiotherapy 3Neoadjuvant Therapy 3Mycophenolic Acid 3Methylprednisolone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Multiple Myeloma × GTP Cyclohydrolase × Clear all
NCT04942067 2023-10-25

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Ascentage Pharma Group Inc.

Phase 1/2 Unknown
108 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡